{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Arvinas, Inc."},"Symbol":{"label":"Symbol","value":"ARVN"},"Address":{"label":"Address","value":"395 WINCHESTER AVENUE,5 SCIENCE PARK, NEW HAVEN, Connecticut, 06511, United States"},"Phone":{"label":"Phone","value":"+1 203 535-1456"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766."},"CompanyUrl":{"label":"Company Url","value":"https://www.arvinas.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Angela Cacace","title":"Chief Scientific Officer"},{"name":"Ian Taylor","title":"President-Research & Development"},{"name":"John A. Grosso","title":"Senior Vice President-R&D Technical Operations"},{"name":"John G. Houston","title":"Chairman, President & Chief Executive Officer"},{"name":"Kimberly Wehger","title":"VP-Information Technology & Corporate Projects"},{"name":"Lisa Sinclair","title":"Senior Vice President-Corporate Operations"},{"name":"Noah Berkowitz","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}